A carregar...
Tivozanib for the treatment of renal cell carcinoma: patient selection and perspectives
Tivozanib is an oral selective vascular endothelial growth factors receptor (VEGFR) tyrosine kinase inhibitor that is recently approved by the European Medicines Agency for the treatment of previously untreated patients with metastatic renal cell carcinoma (mRCC) as well as for those patients with d...
Na minha lista:
| Publicado no: | Int J Nephrol Renovasc Dis |
|---|---|
| Main Authors: | , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Dove
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6526773/ https://ncbi.nlm.nih.gov/pubmed/31190952 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/IJNRD.S169056 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|